Purpose: We evaluated the potential benefit of a second transurethral resection in patients with newly diagnosed pT1 transitional cell carcinoma of the bladder.
Materials And Methods: Between January 2001 and May 2003, 80 patients with stage T1 bladder cancer were included in this protocol in which all patients prospectively received second TUR within 2 to 6 weeks following the initial resection. Patients with incomplete resections were excluded from study. The pathological findings of the second TUR were reviewed.
Results: Of the 80 patients who underwent second resection, 18 (22.5%) had macroscopic tumors before resection. However, with the addition of microscopic tumors, overall residual disease was determined in 27 (33.8%) patients. Of the 27 patients 7 had pTa, 14 had pT1, 3 had pT1+pTis and 3 had pT2 disease. Residual cancers were detected in 5.8%, 38.2% and 62.5% in G1, G2 and G3 tumors, respectively. The risk of residual tumor directly correlated with the grade of the initial tumor (p = 0.009).
Conclusions: Although second TUR dramatically changed the treatment strategy in a small percentage of cases, we strongly recommend performing second TUR in all cases of primary pT1 disease, especially in high grade cases.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/S0022-5347(05)00689-0 | DOI Listing |
Transl Androl Urol
November 2024
Department of Urology, The Second Hospital of Dalian Medical University, Dalian, China.
Background: Nephrogenic adenoma (NA) is a rare benign tumor that can develop at any site of the urinary system, with the bladder being the most common, followed by the urethra, ureters, renal pelvises, etc. Currently, it is unclear what the pathogenesis of NA is. This study discussed a rare case of malignant transformation from NA to mesonephric adenocarcinoma of the bladder.
View Article and Find Full Text PDFCureus
December 2024
General Surgery, Atlas University, Istanbul, TUR.
Int J Urol
December 2024
Department of Urology, Institute of Science Tokyo, Tokyo, Japan.
Background: The efficacy of Vesical Imaging-Reporting and Data System (VI-RADS) for the second transurethral resection (TUR) has not been adequately validated. This study aimed to evaluate the utility of the VI-RADS for high-risk patients with non-muscle-invasive bladder cancer (NMIBC) who are candidates for a second TUR.
Methods: We retrospectively analyzed 116 patients who received magnetic resonance imaging (MRI) prior to an initial TUR and underwent a second TUR for a diagnosis of high-risk NMIBC at the initial TUR.
Asian Pac J Cancer Prev
November 2024
Clinical Oncology Department, Cairo University, Cairo, Egypt.
Purpose: Neoadjuvant chemotherapy (NACT) improves muscle-invasive bladder cancer (MIBC) survival. However, its efficacy is limited to a group of patients. This study explored CK5/6 and GATA3 for molecular subtyping and their prediction to response in patients with MIBC.
View Article and Find Full Text PDFBrain Behav
November 2024
Department of Ultrasound, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.
Objective: This study explored the feasibility of using high-frame-rate ultrasound vector flow imaging (VFI) to quantitatively assess hemodynamics in atherosclerotic internal carotid artery stenosis (ICAS) by evaluating dual-parameters, turbulence index (Tur), and wall shear stress (WSS). Their efficacy in evaluating carotid artery stenosis was also analyzed.
Methods: Fifty-nine patients with ICAS were enrolled.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!